Viking Therapeutics (VKTX) Stock Price & Analysis

VKTX$29.22+1.64 +5.95%
BiotechnologyValue StockGrowth Stock
Compare
Market cap$3.73BEnterprise value$3.02BRevenue (TTM)$0Market position—

Score

69
Bullish
Value
60
Quality
48
Growth
100

AI Analysis

Snapshot

Viking Therapeutics is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 69/100) in Biotechnology. In Biotechnology, that score mix is usable but not one-dimensional. Street targets still imply ~181% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

60
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

100
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

48
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Viking Therapeutics, Inc. (VKTX) last printed $29.22. Equity value is $3.73B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00

About

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.

Viking Therapeutics (VKTX) Stock Price & Analysis

VKTX price $29.22 +1.64 +5.95%

Ticker
VKTX
Price
$29.22
Change
+1.64 +5.95%
Market cap
$3.73B
Forward P/E
12.43
Dividend yield
0.00%
Beta
0.65
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
69
Value
60
Quality
48
Growth
100

Stocklytics score rationale: value 60, quality 48, growth 100.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener